Abstract: The present invention relates generally to the field of chemical formulations in a chemical production facility, and more particularly to providing assistance for producing a chemical formulation in a chemical production facility.

Abstract: A method for operating a clutch of a drive train of a vehicle wherein the clutch, a drive motor primary axis having first wheels that can be driven by the drive motor as first axis and a second axis having second wheels are driven by the drive motor via the clutch as second axis, with the clutch being adjusted between a closed position, wherein a first coupling torque of the clutch is set, and at least one second position differing from the closed position, wherein a second coupling torque of the clutch that is lower than the first coupling torque is set: determining at least one coefficient of friction of a roadway the vehicle is located on; and as a factor of the determined coefficient of friction: adjusting a basic torque of the clutch, with the clutch being prestressed in the second position by the basic torque.

Abstract: A method for operating a clutch of a drive train of a vehicle wherein the clutch, a drive motor primary axis having first wheels that can be driven by the drive motor as first axis and a second axis having second wheels are driven by the drive motor via the clutch as second axis, with the clutch being adjusted between a closed position, wherein a first coupling torque of the clutch is set, and at least one second position differing from the closed position, wherein a second coupling torque of the clutch that is lower than the first coupling torque is set: determining at least one coefficient of friction of a roadway the vehicle is located on; and as a factor of the determined coefficient of friction: adjusting a basic torque of the clutch, with the clutch being prestressed in the second position by the basic torque.

Abstract: A liquid preparation includes an etherified cyclodextrin derivative and a substituted benzimidazol, where the etherified cyclodextrin derivative is one of alpha-, beta, and gamma-cyclodextrin ether.

Abstract: A drinkable pharmaceutical solution includes telmisartan or a pharmaceutically acceptable salt, hydrate or polymorph thereof, where the telmisartan has a concentration of 1 to 10 mg/ml within the drinkable pharmaceutical solution, and the drinkable pharmaceutical solution has a pH of 10.

Abstract: A method for operating a drive train for a motor vehicle, with at least one primary drive axle and at least one secondary drive axle, which are operatively connected to each other via a clutch to an adjustable transmission torque. At the same time it is provided that a vibration amplitude of a vibration of the drive train is determined and in a damping operation type of the drive train, the transmission torque is determined from the vibration amplitude and adjusted on the clutch.

Abstract: A drinkable pharmaceutical solution includes telmisartan or a pharmaceutically acceptable salt, hydrate or polymorph thereof, where the telmisartan has a concentration of 1 to 10 mg/ml within the drinkable pharmaceutical solution, and the drinkable pharmaceutical solution has a pH of 10.

Abstract: A pharmaceutical solution with a pH value of 10 or higher contains an angiotensin II receptor antagonist, where one or more sugar alcohols are present up to a total concentration of 40 wt. % to 70 wt. %.

Abstract: Described herein is a solid tablet that is directly-compressed of powder, including meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.

Abstract: A solid tablet formed through direct compression of powder, the powder comprising meloxicam as an active ingredient and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the meloxicam.

Abstract: A method for operating a drive train for a motor vehicle, with at least one primary drive axle and at least one secondary drive axle, which are operatively connected to each other via a clutch to an adjustable transmission torque. At the same time it is provided that a vibration amplitude of a vibration of the drive train is determined and in a damping operation type of the drive train, the transmission torque is determined from the vibration amplitude and adjusted on the clutch.

Abstract: Described herein is a solid tablet that is directly-compressed of powder, including meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.

Abstract: The invention relates to a solid tablet that is directly-compressed of powder, comprising meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.

Abstract: A liquid preparation includes an etherified cyclodextrin derivative and a substituted benzimidazol, where the etherified cyclodextrin derivative is one of alpha-, beta, and gamma-cyclodextrin ether.

Abstract: A liquid preparation includes an etherified cyclodextrin derivative and a substituted benzimidazol, where the etherified cyclodextrin derivative is one of alpha-, beta, and gamma-cyclodextrin ether.

Abstract: Taste masked multi-layered particles include an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and including a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture including 60-90% (w/w) EC and 10-40% (w/w) HPMC, where the pharmaceutically active ingredient is water-soluble and includes either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions including such particles.

Abstract: The invention relates to novel liquid preparation comprising a substituted benzimidazol, preferably pimobendan as pharmaceutically active compound. In particular, the present invention relates to liquid preparation comprising an etherified cyclodextrin derivative, preferably in a concentration of about 20 to 70% (w/v) and said substituted benzimidazol, preferably in a concentration of about 0.005 to 0.15% (w/w).

Abstract: A pharmaceutical solution with a pH value of 10 or higher contains an angiotensin II receptor antagonist, where one or more sugar alcohols are present up to a total concentration of 40 wt. % to 70 wt. %.

Abstract: A pharmaceutical solution, preferably a drinkable pharmaceutical solution of the active substance telmisartan is described, having a pH above 10 and additionally containing one or more sugar alcohols added to improve the flavour and shelf life, wherein the sugar alcohols or the pharmaceutical solution have a maximum content of 1000 ppm of reducing sugars.

Abstract: A liquid preparation includes an etherified cyclodextrin derivative and a substituted benzimidazol, where the etherified cyclodextrin derivative is one of alpha-, beta, and gamma-cyclodextrin ether.